Clinical Outcomes of HLA-DPB1 Mismatches in 10/10 HLA-Matched Unrelated Donor-Recipient Pairs Undergoing Allogeneic Stem Cell Transplant

Abstract

(n1⁄44) or unrelated CB (n1⁄419). The conditioning regimens were myeloablative in 20 patients and reduced-intensity in 9. Twenty-seven patients achieved neutrophil engraftment at a median day of 19 (range, 10-34). The cumulative incidence of neutrophil engraftment was 93.1% at day 42 (patients engrafted, n1⁄427; dead before day 19, n1⁄42). At 3 years, the cumulative incidence of relapse and non-relapse mortality was 32.3% and 14.0%, respectively. In 15 patients who did not achieve CP before transplantation, 11 patients (73.3%) achieved CR after transplantation. With a median follow-up of survivors of 1144 days (range, 127-3705), overall survival (OS) and event free survival (EFS) at 3 years was 63.2% and 56.3%, respectively. In univariate analysis, the variables that influenced on OS were disease status at transplantation (CP vs. AP/BC, 85% vs. 42%, p1⁄40.012), karyotype (sole Ph-chromosome vs. additional cytogenetic abnormalities, 90% vs. 47.5%, p1⁄40.042) and conditioning regimen (MAC vs. RIC, 72.7% vs. 41.7%, p1⁄40.039). In multivariate analysis, the only variable that influenced on OS was disease status at transplantation (p1⁄40.015). Conclusion: We concluded that allogeneic hematopoietic cell transplantation from any cell sources could become a promising option for the patients with CML in advanced stage, especially if they achieved CP before transplantation.